文献速递冠心病血脂与心血管预防

冠状动脉疾病多基因风险评分在初级预防中的预测效用

Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention.
PubMed 文献 · JAMA Cardiol · 2023-01-01

结果显示PRS预测能力在年轻人群更强,在<50岁者中高PRS相比低PRS的MI风险增加3-4倍;将PRS加入临床ASCVD风险评分可重新分层 borderline 和 intermediate 风险者,指导他汀起始。

要点

  • CAD PRS与MI风险显著相关,且年龄越小预测能力越强(交互P<.001)。
  • 在<50岁人群中,高PRS者MI风险较低PRS者增加3-4倍。
  • 加入PRS可使20% borderline 风险者升为 intermediate 风险而需他汀。

核心结论

  • CAD PRS的预测能力在年轻个体中更强,可用于识别 borderline 和 intermediate 临床风险中应起始他汀治疗的患者。

研究设计与样本

  • 在日本生物银行进行重复分析。

主要发现

  • 随访10年期间4454人发生MI。
  • CAD PRS与MI风险在所有年龄组显著相关,预测能力随年龄增长而减弱(年龄<50岁:每1 SD的HR 1.72,95%CI 1.56-1.89;50-60岁:HR 1.46,95%CI 1.38-1.53;>60岁:HR 1.42,95%CI 1.37-1.48;交互P<.001)。
  • 在<50岁人群中,高PRS者MI风险较低PRS者增加3-4倍。
  • CAD PRS与年龄的显著交互在日本生物银行中重复验证。
  • 在<50岁人群中加入CAD PRS后,borderline 风险者4373人中有591人(20%)重新分层为 intermediate 风险而需起始他汀;borderline 或 intermediate 风险者7477人中有3198人(20%)重新分层为低风险而不需治疗。

关键数值与推荐

  • CAD PRS定义为低(底部20%)、中间、高(顶部20%),基于241个全基因组显著单核苷酸变异。
  • 采用汇总队列方程估计10年ASCVD风险并分类:低(<5%)、borderline(5-<7.5%)、intermediate(7.5-<20%)、高(≥20%)。

临床怎么用

  • 在初级预防中,尤其对年轻人群,可考虑使用CAD PRS辅助他汀起始决策。
  • 对于临床ASCVD风险为borderline或intermediate的年轻个体,CAD PRS可帮助重新分层以指导治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The clinical utility of polygenic risk scores (PRS) for coronary artery disease (CAD) has not yet been established. OBJECTIVE: To investigate the ability of a CAD PRS to potentially guide statin initiation in primary prevention after accounting for age and clinical risk. DESIGN, SETTING, AND PARTICIPANTS: This was a longitudinal cohort study with enrollment starting on January 1, 2006, and ending on December 31, 2010, with data updated to mid-2021, using data from the UK Biobank, a long-term population study of UK citizens. A replication analysis was performed in Biobank Japan. The analysis included all patients without a history of CAD and who were not taking lipid-lowering therapy. Data were analyzed from January 1 to June 30, 2022. EXPOSURES: Polygenic risk for CAD was defined as low (bottom 20%), intermediate, and high (top 20%) using a CAD PRS including 241 genome-wide significant single-nucleotide variations (SNVs). The pooled cohort equations were used to estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk and classify individuals as low (<5%), borderline (5-<7.5%), intermediate (7.5-<20%), or high risk (≥20%). MAIN OUTCOMES AND MEASURES: Myocardial infarction (MI) and ASCVD events (defined as incident clinical CAD [including MI], stroke, or CV death). RESULTS: A total of 330 201 patients (median [IQR] age, 57 [40-74] years; 189 107 female individuals [57%]) were included from the UK Biobank. Over the 10-year follow-up, 4454 individuals had an MI. The CAD PRS was significantly associated with the risk of MI in all age groups but had significantly stronger risk prediction at younger ages (age <50 years: hazard ratio [HR] per 1 SD of PRS, 1.72; 95% CI, 1.56-1.89; age 50-60 years: HR, 1.46; 95% CI, 1.38-1.53; age >60 years: HR, 1.42; 95% CI, 1.37-1.48; P for interaction <.001). In patients younger than 50 years, those with high PRS had a 3- to 4-fold increased associated risk of MI compared with those in the low PRS category. A significant interaction between CAD PRS and age was replicated in Biobank Japan. When CAD PRS testing was added to the clinical ASCVD risk score in individuals younger than 50 years, 591 of 4373 patients (20%) with borderline risk were risk stratified into intermediate risk, warranting initiation of statin therapy and 3198 of 7477 patients (20%) with both borderline or intermediate risk were stratified as low risk, thus not warranting therapy. CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that the predictive ability of a CAD PRS was greater in younger individuals and can be used to better identify patients with borderline and intermediate clinical risk who should initiate statin therapy.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Marston NA, Pirruccello JP, Melloni GEM, et al. Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention. JAMA Cardiol. 2023. PMID: 36576811. doi:10.1001/jamacardio.2022.4466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。